

SPRING GROUP MEETING

Seattle

Radiation Oncology Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa Kachnic, MD
 Executive Officer: Lisa Kachnic, MD

Designates

Breast Committee Liaison: Reshma Jagsi, MD, DPhil
 Cancer Care Delivery Committee Liaison: Eileen Connolly, MD
 Prevention & Epidemiology Committee Liaison: Eileen Connolly, MD
 CNS Working Group Liaison: Tony Wang, MD
 Genitourinary Committee Liaison: James Yu, MD
 Gastrointestinal Committee Liaison: David Horowitz, MD
 Lung Committee Liaison: Henry Park, MD
 Lymphoma Committee Liaison: Nick Figura, MD
 Melanoma Committee Liaison: Evan Wuthrick, MD
 Symptom Control & QOL Committee Liaison: Erin Gillespie, MD, MPH
 Statistical Liaison: Sam Callis, MS

Time/Location

Saturday, April 6, 2024 9:30 a.m. - 11:30 a.m.
 Room: Ashnola/301 (Level 3)

Agenda

- 9:30 - 9:35 am Welcome - Chul S. Ha, MD
 9:35 - 9:40 am Report from Executive Officer - Lisa Kachnic, MD
 9:40 - 9:45 am Update from IROC - T.J. FitzGerald, MD
 9:45 - 9:50 am Update from NCI - Jacek Capala, Ph.D., DSc
 9:50 - 11:15 am Reports by Committees

Breast Report by Liaison: Reshma Jagsi, MD, DPhil

- A Phase II Randomized Trial of Olaparib Administered Concurrently with RT vs RT Alone for Inflammatory Breast Cancer (S1706)- Reshma Jagsi, MD, DPhil
- Randomized phase III trial of multimodality therapy in each subtype of stage IV oligometastatic breast cancer vs palliative therapy- Shane Stecklein, MD
- Re-radiation trial for in-breast recurrence - Eileen Connolly, MD
- CDK 4/6 inhibition concurrent with RT for ER+ locally advanced breast cancer – Corey Speers, MD
- Hope Foundation Proposal- Rachel Jimenez, MD & Corey Speers, MD

CNS Report by Liaison: Tony Wang, MD

- Phase II study of atezolizumab and tocilizumab with radiotherapy in patients with newly diagnosed MGMT unmethylated glioblastoma - Tony Wang, MD
- TRC102 and temozolomide in patients with refractory and first line GBM - Tony Wang, MD
- Spine SBRT protocol in concept stage - Tony Wang, MD

Gastrointestinal Report by Liaison: David Horowitz, MD

- Induction immunotherapy for localized anal cancer - David Horowitz, MD

Genitourinary Report by Liaison: James Yu, MD

- The ART of Bladder Preservation - Leslie Ballas, MD
- Phase III randomized trial of standard systemic therapy +/- definitive therapy (surgery or radiation) of the primary tumor in metastatic prostate cancer (S1802) - Richard Valicenti, MD
- Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer (S1806) - Sameer Jhavar, MD
- Secondary Analysis of SWOG 9312/1314/8710 - Steven Seyedin, MD

Lung Report by Liaison: Henry Park, MD

- Sequencing of immunotherapy and chemotherapy in unresectable stage III non-small cell lung cancer - Henry Park, MD
- A randomized phase III trial of induction/consolidation Atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC (S1914) - Megan Daly, MD
- MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation: a randomized phase III trial in small-cell lung cancer (S1827) - Chad Rusthoven, MD
- A pilot study of hypofractionated radiotherapy followed by Atezolizumab consolidation in stage II or III NSCLC patients with borderline performance status (S1933) - Timur Mitin, MD
- NRG CC009: Phase III trial of SRS versus hippocampal-avoidant whole brain radiotherapy for 10 or fewer brain metastases from small cell lung cancer - Chad Rusthoven, MD

Radiation Oncology Committee

Lymphoma Report by Liaison: Nicholas Figura, MD

Melanoma Report by Liaison: Evan Wuthrick, MD

- Secondary analysis for S1404 - Evan Wuthrick, MD

Sarcoma

- Phase III Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk, Resectable Sarcoma (S2310) - Jeremy Harris, MD

Cancer Control & Prevention Committee/ Cancer Care Delivery

Committee Report by Liaison: Eileen Connolly, MD

- Radiation therapy for high-risk asymptomatic bone metastases: A pragmatic multicenter randomized phase III clinical trial - Erin Gillespie, MD
- Harnessing implementation science and digital health to promote evidence-based management of cancer related fatigue - Erin Gillespie, MD

Symptom Control & Quality of Life Committee Report by Liaison:

Erin Gillespie, MD

11:15-11:20 pm Announcements

Search for liaisons for Cancer Survivorship Committee, Immunotherapeutics Committee, and Early Therapeutics & Rare Cancer Committee.

11:20-11:25 pm Open Forum

11:25-11:30 pm Closing Remarks - Chul S. Ha, MD

